Multiple Cardiac Sensors for the Management of Heart Failure

a study on Heart Failure

Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
estimated completion
Principal Investigator
Byron Lee, MD
Photo of Byron Lee
Byron Lee

Description

Summary

The MANAGE-HF study is a multi-center, global, prospective, open label, multi-phase trial intended to evaluate the clinical efficacy of the HeartLogic heart failure diagnostic feature.

Details

Phase I of the MANAGE-HF trial is not randomized, and is intended to evaluate the clinical integration of HeartLogic for managing patients with heart failure. There are no endpoints.

Phase II of the MANAGE-HF trial will assess the clinical effectiveness of remote monitoring of heart failure patients with implanted CRT-D or ICD cardiac devices that contain the diagnostic feature HeartLogic. This feature uses S1 and S3 heart sounds, night time heart rate, thoracic impedance, and respiration to alert clinicians when a patient's heart failure is worsening. The MANAGE-HF study will compare remote monitoring using HeartLogic alerts to drive heart failure care against patients with remote monitoring but without HeartLogic alerts.

Keywords

Heart Failure, Congestive heart failure diagnostics heart sounds CRT-D ICD remote monitoring HeartLogic ON HeartLogic OFF

Eligibility

You can join if…

Open to people ages 18 years and up

  1. Subject is age 18 or above, or of legal age to give informed consent
  2. Implanted with an cardiac resynchronization therapy defibrillator (CRT-D) or implantable cardioverter-defibrillator (ICD) device that has HeartLogic
  3. Current symptomatic heart failure or New York Heart Association Class II or III at the time of enrollment
  4. Remotely monitored by LATITUDE 5.0 (or future versions)
  5. Willing and capable of participating in all study visits and complying with medication/treatment requirements associated with this clinical study at an approved clinical study center.
  6. Meet at least one of the three following conditions:
  7. At least one documented hospitalization with a primary diagnosis of worsening for heart failure during the 12 months prior to enrollment; or
  8. Unscheduled outpatient visit with IV diuretic therapy for acute worsening of HF during 90 days prior to enrollment; or
  9. N-terminal-pro brain natriuretic peptide (NT-proBNP) greater than 600 pg/mL or brain natriuretic peptide (BNP) greater than 150 pg/mL at any time during 90 days prior to enrollment

You CAN'T join if...

  1. The subject is unable to sign or refuses to sign the patient informed consent
  2. Symptomatic heart failure at rest or New York Heart Association Class IV at the time of enrollment
  3. The subject is implanted with unipolar right atrial or right ventricular leads
  4. Subject has received or is scheduled to receive a heart transplant or ventricular assist device within the next 6 months
  5. Subject is pregnant or planning to become pregnant during the study
  6. Subject is enrolled in any other concurrent study (without prior written approval from Boston Scientific, excluding registries)
  7. Glomerular filtration rate <25 mL/min who are non-responsive to diuretic therapy or are on chronic renal dialysis
  8. Regularly scheduled intravenous heart failure therapy (for example inotropes or diuretics)
  9. A life expectancy of less than 12 months per clinician discretion
  10. . APPLICABLE TO PHASE II ONLY: Subject enrolled in Phase I of MANAGE-HF
  11. . APPLICABLE TO PHASE II ONLY: Subject has been managed with HeartLogic Alerts ON at anytime within the past 6 months.

Locations

  • University of California, San Francisco accepting new patients
    San Francisco California 94143 United States
  • Cardiovascular Consultants accepting new patients
    Oakland California 94609 United States

Lead Scientist at UCSF

  • Byron Lee, MD
    CLINICAL INTERESTS: Dr. Lee is a Cardiologist and a Cardiac Electrophysiologist. His main clinical interests include conduction disorders, arrhythmias, catheter ablation, implantable devices (including pacemakers, defibrillators and biventricular defibrillators), lead extraction, atrial fibrillation, atrial flutter, supraventricular tachycardias, ventricular tachycardias, and sudden death.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Boston Scientific Corporation
ID
NCT03237858
Study Type
Interventional
Last Updated
Contact us about this trial